Beranda › Limfoma Folikuler › Indiana
Uji klinis Limfoma Folikuler di Indiana
7 studi untuk Limfoma Folikuler mencari peserta di lokasi di Indiana.
Kota di Indiana
Teks studi resmi (Bahasa Inggris)
5HTP Regulation Of Asthma In Children
- Indiana University, Indianapolis
Menerima pesertaFase 2
Usia 8 hingga 18 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT04160910A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Fort Wayne
Menerima pesertaFase 3
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06549595A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Investigative Clinical Research of Indiana, Noblesville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06091254SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Indiana University, Indianapolis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Indiana Blood and Marrow Transplantation, Indianapolis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Indiana University and Comprehensive Cancer Center, Indianapolis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06149286AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- American Oncology Partners, Fort Wayne
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Des 2025 · NCT05602363Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.